Newsroom

Sight Sciences Reports Third Quarter 2023 Financial Results and Withdraws Guidance for Full Year 2023

PDF Version   MENLO PARK, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, today reported financial results for the third quarter ended September 30, 2023 and withdrew […]

read more +
Sight Sciences to Report Third Quarter 2023 Financial Results on November 7, 2023

PDF Version MENLO PARK, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, today announced it will report financial results for the third quarter ended September 30, 2023, […]

read more +
Sight Sciences Announces New, Large-Scale MIGS Data from 41st Congress of ESCRS Demonstrating TCOR™ Using OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma

PDF Version   Efficacy of the Three Most Commonly Used MIGS Technologies plus Cataract Surgery and Cataract Surgery Alone Were Evaluated and Compared in over 100,000 Glaucoma Patient Eyes   MENLO PARK, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on developing and commercializing […]

read more +
Sight Sciences Appoints Matt Link as Chief Commercial Officer

PDF Version Former NuVasive President helped scale high growth medical device company to over $1 billion in revenue MENLO PARK, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ […]

read more +
Sight Sciences Provides Revenue Guidance for the Third Quarter of 2023 and Updates Revenue Guidance for Full Year 2023

PDF Version MENLO PARK, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, today announced third quarter 2023 revenue guidance and updated its revenue guidance for full year […]

read more +
Sight Sciences Reports Second Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023

PDF Version MENLO PARK, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, today reported financial results for the second quarter ended June 30, 2023 and reaffirmed guidance […]

read more +
Sight Sciences to Report Second Quarter 2023 Financial Results on August 3, 2023

PDF Version MENLO PARK, Calif., July 20, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, today announced it will report financial results for the second quarter ended June 30, 2023, after the market close on […]

read more +
Sight Sciences Announces Addition of New Director Catherine Mazzacco

PDF Version MENLO PARK, Calif., June 09, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announces that Catherine Mazzacco was elected to the Company’s board of directors at its Annual Meeting […]

read more +